ACE and COVID-19: However, to date, there are no conclusive data demonstrating beneficial or adverse outcomes with background use of ACE-inhibitors, ARBs or other RAS antagonists among COVID-19 patients with a history of cardiovascular disease treated with these drugs (69–71).